A-836,339

A-836,339
Legal status
Legal status	CA: Schedule II;
Identifiers
	IUPAC name N-[3-(2-methoxyethyl)-4,5-dimethyl-1,3-thiazol-2-ylidene]-2,2,3,3-tetramethylcyclopropane-1-carboxamide;
CAS Number	959746-77-1 ;
PubChem CID	17754357;
ChemSpider	26286892 ;
UNII	Z6Y1J258EG;
CompTox Dashboard (EPA)	DTXSID601010006 ;
Chemical and physical data
Formula	C16H26N2O2S
Molar mass	310.46 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Cc1c(sc(=NC(=O)C2C(C2(C)C)(C)C)n1CCOC)C;
	InChI InChI=1S/C16H26N2O2S/c1-10-11(2)21-14(18(10)8-9-20-7)17-13(19)12-15(3,4)16(12,5)6/h12H,8-9H2,1-7H3 ; Key:JKGIMVBQKSRTGX-UHFFFAOYSA-N ;
	(what is this?) (verify)

A-836,339 is a drug developed by Abbott Laboratories that acts as a potent cannabinoid receptor full agonist. It is selective for CB₂, with K_i values of 0.64 nM at CB₂ vs 270 nM at the psychoactive CB₁ receptor, but while it exhibits selective analgesic, anti-inflammatory and anti-hyperalgesic effects at low doses,^[1] its high efficacy at both targets results in typical cannabis-like effects appearing at higher doses, despite its low binding affinity for CB₁.^[2] In 2012 A-836,339 was detected via X-ray crystallography in a "dubious product" sold in Japan, though the product was described as a white powder, not herbal incense, it was suggested to be for human consumption.^[3]